drugset
drugset / Trial / NCT04896385

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385 ↗

Phase 2 Completed 60 enrolled Incyte Corporation
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.

Timeline

Start
2021-06-23
Primary completion
2022-11-17
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Topical

Indications

vitiligo